Difference between revisions of "Eribulin (Halaven)"
(Created page with "==General information== Class/mechanism: <ref name="insert">[http://www.halaven.com/sites/default/files/HALAVEN_full_Prescribing_Information.pdf Eribulin (Halaven) package insert...") |
|||
Line 1: | Line 1: | ||
==General information== | ==General information== | ||
− | Class/mechanism: <ref name="insert">[http://www.halaven.com/sites/default/files/HALAVEN_full_Prescribing_Information.pdf Eribulin (Halaven) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/eribulin.pdf Eribulin (Halaven) package insert (locally hosted backup)]</ref> | + | Class/mechanism: Non-taxane microtubule dynamics inhibitor. Inhibits the growth phase of microtubules and aggregates tubulin into inactive aggregates. Does not affect the shortening phase. Disruption of mitotic spindles interferes with mitosis, leads to G2/M cell-cycle block, and apoptotic cell death.<ref name="insert">[http://www.halaven.com/sites/default/files/HALAVEN_full_Prescribing_Information.pdf Eribulin (Halaven) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/eribulin.pdf Eribulin (Halaven) package insert (locally hosted backup)]</ref> |
− | <br>Route: | + | <br>Route: IV |
− | <br>Extravasation: | + | <br>Extravasation: no information |
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. |
Revision as of 18:15, 10 January 2012
General information
Class/mechanism: Non-taxane microtubule dynamics inhibitor. Inhibits the growth phase of microtubules and aggregates tubulin into inactive aggregates. Does not affect the shortening phase. Disruption of mitotic spindles interferes with mitosis, leads to G2/M cell-cycle block, and apoptotic cell death.[1][2]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].